ISCSGCON 2026Conference Report & Scientific Legacy

The inaugural scientific session established the biological and translational foundations upon which modern regenerative medicine is built. The deliberations traversed the evolving landscape of cellular therapeutics, emphasizing the scientific principles governing stem cell biology, cellular differentiation, tissue repair, and regenerative signaling pathways. Particular attention was devoted to induced pluripotent stem cell (iPSC) technologies, which have revolutionized disease modeling, drug discovery, and personalized regenerative interventions through their ability to recapitulate pluripotency while circumventing many ethical concerns associated with embryonic stem cells.

The session further explored the biological distinctions between peripheral blood–derived stem cells and bone marrow–derived progenitors, highlighting their differential regenerative capacities, immunomodulatory profiles, and clinical applicability across diverse pathological conditions. Emerging evidence regarding the post-administration behavior of mesenchymal stromal cells (MSCs) was discussed, underscoring the increasingly accepted paradigm that their therapeutic efficacy may be mediated less by direct engraftment and more through paracrine signaling and immunological modulation.

A significant focus was placed on adipose-derived regenerative products, including stromal vascular fraction (SVF) and microfat technologies. Comparative analyses examined cellular composition, mechanisms of action, and current evidence supporting their use in musculoskeletal disorders. Discussions highlighted the need for procedural standardization, regulatory oversight, and rigorous clinical validation before widespread adoption. The session concluded with an interactive "Regenerative Adalat," where experts critically examined prevailing controversies, translational barriers, and future opportunities, establishing the intellectual foundation for the subsequent multidisciplinary discussions throughout the conference.

The prestigious Past President Oration offered a reflective yet forward-looking perspective on innovation in regenerative medicine through the lens of surgical practice. Drawing from extensive clinical experience, the speaker presented a compelling narrative of how scientific curiosity, translational research, and clinical innovation can converge to transform patient outcomes. The discourse emphasized the historical evolution of regenerative concepts from experimental observations to clinically applicable interventions.

Particular focus was placed on identifying unmet clinical challenges and leveraging biological principles to develop innovative treatment strategies. The session illustrated how surgeon-scientists play a pivotal role in bridging laboratory discoveries and real-world patient care. Beyond technical innovations, the oration highlighted the importance of perseverance, ethical responsibility, and interdisciplinary collaboration in advancing regenerative medicine.

The oration served as both an academic reflection and an inspirational call to action, encouraging young clinicians and researchers to contribute actively to the evolution of regenerative science. By integrating clinical wisdom with scientific foresight, the session underscored the responsibility of the current generation to transform promising biological concepts into safe, effective, and accessible therapies for future patients.

This multidisciplinary session showcased the extraordinary breadth of regenerative medicine beyond the musculoskeletal domain. Presentations highlighted how regenerative technologies are increasingly influencing reproductive medicine, fetal therapy, wound healing, hepatology, and paediatric surgery, illustrating the universal relevance of regenerative principles across organ systems.

Clinical applications of mesenchymal stem cells in refractory thin endometrium demonstrated how cellular therapies are creating new possibilities in reproductive medicine. Equally compelling were discussions on innovative biological approaches for sealing amniotic fluid leaks, representing a novel frontier in fetal and maternal health. The role of regenerative interventions in chronic diabetic foot ulcers further emphasized the potential of cellular therapies to address conditions characterized by impaired healing and chronic inflammation.

The session also explored regenerative strategies targeting liver fibrosis and hepatic regeneration, with speakers discussing the complex interplay between cellular therapies, extracellular signaling pathways, and tissue remodeling mechanisms. A recurring theme was the importance of understanding tissue-specific microenvironments and disease biology when designing regenerative interventions, reinforcing that regenerative medicine is a unifying scientific framework with applications across virtually every field of medicine.

This highly specialized session focused on regenerative ophthalmology, a rapidly evolving field that integrates stem cell biology, tissue engineering, biomaterials, and advanced manufacturing technologies to address vision-threatening disorders. Discussions highlighted the remarkable regenerative potential of ocular tissues and the emerging role of stem cells in restoring corneal integrity, ocular surface function, and visual performance.

Particular emphasis was placed on the integration of three-dimensional bioprinting technologies with regenerative therapeutics, enabling the development of biomimetic tissue constructs designed to replicate complex ocular structures. The session explored novel approaches for enhancing corneal wound healing following injury and disease, emphasizing the role of cellular therapies in modulating inflammation, promoting epithelial regeneration, and reducing scar formation.

Speakers also discussed the challenges associated with translating regenerative ophthalmic therapies from laboratory research to clinical application — cellular delivery systems, long-term safety, manufacturing consistency, and regulatory approval pathways. A major takeaway was the growing convergence of regenerative biology and biomedical engineering, offering a glimpse into a future where biological restoration replaces symptomatic management for blindness and visual impairment.

This session provided a comprehensive overview of ongoing clinical and translational investigations that are shaping the future of regenerative medicine. The presentations highlighted the critical role of structured clinical research in validating emerging biological therapies and ensuring their safe integration into routine practice.

Topics ranged from experimental stem cell interventions for diabetes mellitus to innovative applications of autologous adult live cultured osteoblasts in avascular necrosis of the femoral head. Investigators shared valuable insights regarding study design, patient selection, outcome assessment, and the practical challenges encountered during clinical translation. Particularly noteworthy were discussions surrounding dual-route fetal mesenchymal stem cell therapy for severe osteogenesis imperfecta, illustrating how regenerative medicine is increasingly targeting rare and complex disorders that previously lacked effective treatment options.

The session reinforced the importance of evidence-based medicine in a field often characterized by rapid innovation and commercial enthusiasm. Speakers emphasized that robust clinical trials remain essential for distinguishing scientifically validated therapies from interventions supported primarily by anecdotal evidence, underscoring the value of multicentric collaboration and long-term follow-up in generating high-quality evidence.

This session addressed one of the most critical challenges in regenerative medicine: translating promising laboratory discoveries into safe, effective, and regulatory-compliant clinical therapies. The presentations explored India's evolving regulatory landscape governing stem cell and gene therapy products, with detailed discussions on the ethical, scientific, and legal considerations that must guide clinical implementation.

Another major focus was the emerging role of allogenic stem cell therapies in osteoarthritis. Speakers examined the scientific rationale for utilizing donor-derived cellular products, including their scalability, standardization potential, and immunomodulatory properties, while critically reviewing current evidence and unresolved questions regarding long-term outcomes and regulatory oversight.

The session emphasized that successful translation requires more than biological efficacy alone — manufacturing quality, product characterization, reproducibility, ethical governance, and health-economic considerations are equally important determinants of clinical success. A recurring theme was the necessity of fostering collaboration between clinicians, scientists, industry stakeholders, and regulatory authorities, underscoring the maturation of regenerative medicine into a structured clinical science governed by rigorous translational principles.

The keynote lecture explored the rapidly evolving interface between regenerative biology and spinal surgery, focusing on the synergistic use of cellular therapeutics and biomaterial scaffolds to enhance tissue repair and spinal fusion outcomes. Contemporary spinal surgery increasingly demands biological solutions capable of addressing degenerative disc disease, pseudoarthrosis, vertebral defects, and complex reconstructive challenges.

The session highlighted how mesenchymal stem cells, osteoprogenitor populations, and biologically active matrices can be integrated within scaffold-based platforms to create microenvironments conducive to tissue regeneration rather than simple structural replacement. Particular emphasis was placed on the principles of tissue engineering, including scaffold architecture, cellular viability, mechanotransduction, vascularization, and osteoinductive signaling.

Emerging evidence from translational and clinical studies demonstrated how cell-scaffold constructs can enhance fusion rates, improve biomechanical stability, and potentially reduce dependence on traditional autologous graft sources. A major scientific takeaway was that successful spinal regeneration requires a carefully orchestrated interaction between cells, scaffolds, growth factors, and host biology — offering valuable insight into how regenerative technologies may fundamentally transform spinal reconstruction.

The Gold Medal Paper Session represented one of the most academically stimulating components of the conference, showcasing high-quality clinical research conducted by emerging investigators in regenerative medicine. The presentations reflected the growing maturity of orthobiologic research and emphasized the importance of evidence generation in guiding clinical decision-making.

Topics included platelet-rich plasma (PRP) for sacroiliitis, platelet-rich fibrin (PRF) augmentation in arthroscopic meniscal repair, autologous cytokine-rich serum in osteoarthritis, PRP interventions for partial anterior cruciate ligament injuries, and regenerative approaches for osteochondral lesions. Collectively, these studies illustrated the expanding role of autologous biological therapies in addressing musculoskeletal disorders while minimizing surgical morbidity.

A recurring theme was the importance of patient selection, biological product characterization, standardized preparation protocols, and outcome measurement. Investigators demonstrated how variations in cellular concentration, cytokine profiles, and delivery techniques can significantly influence clinical outcomes. The session reinforced the importance of cultivating young clinician-scientists who will contribute to the future development of evidence-based regenerative therapeutics.

This forward-looking session examined one of the most exciting frontiers in regenerative medicine: cell-free biological therapeutics. Exosomes and extracellular vesicles have emerged as powerful mediators of intercellular communication and are increasingly viewed as potential alternatives to conventional stem cell therapies.

Presentations explored the biological mechanisms through which extracellular vesicles transfer proteins, microRNAs, messenger RNAs, and bioactive molecules to target tissues, thereby influencing inflammation, angiogenesis, immune regulation, and tissue regeneration. Particular emphasis was placed on exosome-based therapeutics in musculoskeletal, cardiovascular, and neonatal medicine — including the therapeutic potential of platelet-derived exosomes for myocardial regeneration and extracellular vesicles derived from umbilical cord mesenchymal stem cells with their immunomodulatory properties.

The speakers emphasized that exosome-based therapeutics may overcome several challenges associated with live-cell therapies, including storage limitations, immunogenicity concerns, manufacturing complexities, and regulatory barriers. Nevertheless, significant challenges remain regarding isolation techniques, dosage standardization, quality control, and long-term safety evaluation. The session provided attendees with an exciting glimpse into a future where biologically active vesicles may become central components of regenerative treatment strategies.

The Presidential Oration delivered a comprehensive overview of the historical evolution, current status, and future trajectory of stem cell therapies within India. The presentation traced the progression of regenerative medicine from experimental laboratory concepts to government-approved therapeutic applications, with particular emphasis on the regulatory framework established by Indian scientific and governmental bodies to ensure patient safety and scientific accountability.

The session reviewed milestones achieved in stem cell research, including advancements in hematological disorders, tissue regeneration, immune modulation, and cellular therapeutics. Attention was also directed toward the challenges faced during translation, including standardization, manufacturing quality, ethical oversight, and public misconceptions regarding stem cell treatments.

A central theme was the need for clinicians to balance innovation with scientific rigor. The oration emphasized that sustainable growth in regenerative medicine depends upon evidence-based adoption rather than unregulated commercialization, and concluded with a visionary outlook for India's role in the global regenerative medicine landscape — highlighting opportunities for international collaboration, indigenous innovation, and translational research.

This session focused on contemporary orthobiologic interventions addressing cartilage degeneration, fracture healing, osteoarthritis, and growth plate pathology. Discussions highlighted how regenerative medicine is increasingly becoming integrated into routine orthopaedic practice.

Topics included microfracture combined with BMAC for advanced osteoarthritis, orthobiologic strategies for non-union management, autologous concentrated serum therapies, and chondrocyte-based regenerative approaches for growth plate arrest. The presentations collectively emphasized the biological principles underlying tissue repair and musculoskeletal regeneration, with particular attention devoted to identifying factors responsible for treatment failure, especially in platelet-rich plasma therapies.

A major scientific message was that regenerative orthopaedics should not be viewed as a replacement for established surgical principles but rather as a complementary biological strategy capable of enhancing healing and functional recovery, progressively reshaping orthopaedic treatment algorithms and expanding joint-preserving treatment options.

This distinguished oration provided a unique long-term perspective on the clinical application of adipose-derived mesenchymal stem cell therapies. Drawing upon experience from more than 5000 treated patients, the speaker presented one of the largest real-world datasets discussed during the conference.

The session examined the biological rationale for utilizing adipose-derived regenerative products and reviewed clinical outcomes across a spectrum of musculoskeletal conditions. Particular attention was directed toward patient selection, procedural standardization, safety monitoring, and long-term follow-up.

Importantly, the presentation highlighted how large-scale clinical experience can complement controlled research studies by providing insights into durability, reproducibility, and practical implementation challenges. The oration underscored the importance of evidence accumulation through both formal clinical trials and meticulously documented clinical registries.

This unique keynote expanded the conference discourse beyond biological regeneration to encompass holistic health, consciousness, and human well-being. The presentation explored the relationship between mental health, stress modulation, emotional resilience, and physiological healing.

Scientific evidence linking neuroendocrine pathways, inflammation, immune regulation, and psychological well-being was discussed in the context of regenerative medicine. The session emphasized that successful healing extends beyond cellular interventions and may be influenced by behavioral, psychological, and lifestyle factors, encouraging attendees to adopt a broader view of patient care in which biological therapies are integrated with strategies aimed at optimizing overall health and resilience.

This interdisciplinary symposium explored regenerative applications within male reproductive and sexual medicine. Presentations critically examined current evidence regarding regenerative interventions for erectile dysfunction, infertility, and microsurgical reconstruction.

Speakers emphasized the need to distinguish evidence-based therapies from commercial hype. Discussions focused on rational treatment algorithms, outcome assessment, and the biological mechanisms through which regenerative therapies may influence vascular, neural, and tissue repair pathways. The symposium highlighted the growing role of regenerative medicine in andrology while emphasizing the necessity for rigorous scientific validation before widespread adoption.

This session explored regenerative strategies in oral and maxillofacial medicine, with particular emphasis on platelet concentrates, osseointegration enhancement, and tissue engineering applications.

Presentations demonstrated how biologically active products such as PRF and mesenchymal progenitor cell–based constructs can accelerate healing, improve implant integration, and enhance tissue regeneration. The session highlighted the remarkable translational success of regenerative concepts within dental practice and showcased future opportunities for craniofacial tissue engineering.

The keynote on CAR-T cell therapy highlighted one of the most transformative developments in modern translational medicine. The lecture detailed the scientific journey from basic immunological discovery to the development of indigenous gene therapy platforms capable of targeting malignant diseases with unprecedented precision.

Discussions explored cellular engineering, translational research pathways, manufacturing challenges, regulatory frameworks, and societal impact. The session demonstrated how regenerative medicine, gene therapy, and immunotherapy are increasingly converging to create highly personalized therapeutic approaches.

This highly relevant orthopaedic session focused on cartilage repair, bone regeneration, osteonecrosis management, and advanced orthobiologic interventions. Presentations explored cultured chondrocytes, scaffold-assisted cartilage repair, rhBMP-2 biology, and evolving strategies for femoral head preservation.

Particular attention was devoted to the emerging "Bimodal Approach" combining enhanced core decompression with bone marrow aspirate concentrate for osteonecrosis. Discussions highlighted how biological augmentation may improve vascular restoration, cellular repopulation, and structural preservation of the femoral head. The session reinforced the growing transition from replacement strategies toward biological preservation and tissue restoration within orthopaedic surgery.

The concluding scientific session synthesized contemporary perspectives on regenerative orthopaedics while exploring future directions. Topics included stem cell therapies for arthritis, regenerative approaches for genetic disorders, and comparative analyses of BMAC and PRP in osteoarthritis management.

The discussions emphasized the need for personalized biological therapies tailored to disease stage, tissue pathology, and patient-specific biological characteristics. Comparative evaluations highlighted the strengths and limitations of various orthobiologic products and underscored the importance of evidence-driven clinical decision-making.

Serving as the final scientific forum of the conference, this session successfully integrated lessons from previous discussions and provided a forward-looking perspective on the future of musculoskeletal regeneration, reinforcing that regenerative orthopaedics is evolving toward increasingly sophisticated, mechanism-based interventions aimed at restoring tissue function while preserving native anatomy.